Enasidenib

Drug Profile

Enasidenib

Alternative Names: AG 221; CC-90007; IDH2 inhibitor - Agios/Celgene

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Celgene Corporation
  • Class Antineoplastics; Propanols; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 27 Oct 2016 Celgene and Agios announce intention to submit NDA to the US FDA for enasidenib in Acute myeloid leukaemia in 2016 (9205792; 9206235)
  • 18 Oct 2016 The Leukemia and Lymphoma Society plans a Beat AML Master trial for Acute myeloid leukaemia in USA
  • 01 Aug 2016 Agios Pharmaceuticals completes phase-I/II clinical trials in Solid tumours (first-line therapy) in USA (PO) (NCT02273739)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top